Almeida C, Palmeira A, Valente M, Correia-da-Silva G, Vinggaard A, Sousa M
Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338407
PMC: 11434916.
DOI: 10.3390/ph17091245.
Gunther J, Schuler G, Teppa E, Furbass R
Int J Mol Sci. 2024; 25(3).
PMID: 38338720
PMC: 10855386.
DOI: 10.3390/ijms25031440.
Krymov S, Salnikova D, Dezhenkova L, Bogdanov F, Korlyukov A, Scherbakov A
Pharmaceuticals (Basel). 2024; 17(1).
PMID: 38256865
PMC: 10818622.
DOI: 10.3390/ph17010032.
Hajirahimkhan A, Howell C, Bartom E, Dong H, Lantvit D, Xuei X
Sci Rep. 2023; 13(1):8734.
PMID: 37253812
PMC: 10229614.
DOI: 10.1038/s41598-023-34762-z.
Wu Q, Qian W, Sun X, Jiang S
J Hematol Oncol. 2022; 15(1):143.
PMID: 36209184
PMC: 9548212.
DOI: 10.1186/s13045-022-01362-9.
.
Teslenko I, Watson C, Chen G, Lazarus P
Mol Pharmacol. 2022; 102(5).
PMID: 35953090
PMC: 9595203.
DOI: 10.1124/molpharm.122.000545.
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
Bahrami N, Jabeen S, Tahiri A, Sauer T, Presterud Odegard H, Geisler S
Breast Cancer Res Treat. 2021; 190(3):435-449.
PMID: 34554372
PMC: 8558290.
DOI: 10.1007/s10549-021-06399-x.
A Fluorometric CYP19A1 (Aromatase) Activity Assay in Live Cells.
Heidary D, Kriger S, Hachey A, Glazer E
ChemMedChem. 2021; 16(18):2845-2850.
PMID: 34224206
PMC: 9276262.
DOI: 10.1002/cmdc.202100326.
Melatonin as an Oncostatic Molecule Based on Its Anti-Aromatase Role in Breast Cancer.
Jin Y, Choi Y, Heo K, Park S
Int J Mol Sci. 2021; 22(1).
PMID: 33406787
PMC: 7795758.
DOI: 10.3390/ijms22010438.
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design.
Das A, Weigle A, Arnold W, Kim J, Carnevale L, Huff H
Pharmacol Ther. 2020; 215:107601.
PMID: 32534953
PMC: 7773148.
DOI: 10.1016/j.pharmthera.2020.107601.
Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
Rendic S, Guengerich F
Drug Metab Rev. 2019; 50(3):256-342.
PMID: 30717606
PMC: 6421578.
DOI: 10.1080/03602532.2018.1483401.
Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Luo S, Chen G, Truica C, Baird C, Xia Z, Lazarus P
Drug Metab Dispos. 2018; 46(12):1867-1878.
PMID: 30257855
PMC: 7333658.
DOI: 10.1124/dmd.118.081166.
A Fungal P450 Enzyme from Thanatephorus cucumeris with Steroid Hydroxylation Capabilities.
Lu W, Chen X, Feng J, Bao Y, Wang Y, Wu Q
Appl Environ Microbiol. 2018; 84(13).
PMID: 29728383
PMC: 6007115.
DOI: 10.1128/AEM.00503-18.
Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.
Yesil Devecioglu T, Aydogan F, Omurtag G, Bese N, Sardas S
North Clin Istanb. 2018; 5(1):6-13.
PMID: 29607425
PMC: 5864710.
DOI: 10.14744/nci.2017.55822.
Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies.
Rampogu S, Son M, Park C, Kim H, Suh J, Lee K
Biomed Res Int. 2018; 2017:2105610.
PMID: 29312992
PMC: 5664374.
DOI: 10.1155/2017/2105610.
Comprehensive and Automated Linear Interaction Energy Based Binding-Affinity Prediction for Multifarious Cytochrome P450 Aromatase Inhibitors.
van Dijk M, Ter Laak A, Wichard J, Capoferri L, Vermeulen N, Geerke D
J Chem Inf Model. 2017; 57(9):2294-2308.
PMID: 28776988
PMC: 5615371.
DOI: 10.1021/acs.jcim.7b00222.
Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.
Peterson A, Xia Z, Chen G, Lazarus P
Pharmacol Res Perspect. 2017; 5(3):e00313.
PMID: 28603632
PMC: 5464342.
DOI: 10.1002/prp2.313.
Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S, Chen G, Truica C, Baird C, Leitzel K, Lazarus P
Pharmacogenomics J. 2017; 18(2):295-300.
PMID: 28534527
PMC: 5700874.
DOI: 10.1038/tpj.2017.18.
Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies.
Mojaddami A, Sakhteman A, Fereidoonnezhad M, Faghih Z, Najdian A, Khabnadideh S
Res Pharm Sci. 2017; 12(1):21-30.
PMID: 28255310
PMC: 5333476.
DOI: 10.4103/1735-5362.199043.
Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
Platt A, Xia Z, Liu Y, Chen G, Lazarus P
Pharmacogenet Genomics. 2016; 26(8):370-80.
PMID: 27111237
PMC: 5088049.
DOI: 10.1097/FPC.0000000000000226.